Analytical Data
-
Gene name
ASAH1
- Application
-
Alternative Names
Acylsphingosine deacylase N-acylsphingosine amidohydrolase Putative 32KDA heart protein Short name:PHP32
-
Species
Human
-
Source
E. coli
-
Tag
N- His-SUMO
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q13510
-
Expression Region
22-395aa
-
Molecular Weight
58.7 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The ASAH1 (alkaline ceramidase 1) protein plays a crucial role in sphingolipid metabolism, specifically in the hydrolysis of ceramide into sphingosine and free fatty acids, thereby influencing various cellular processes, including apoptosis, cell proliferation, and inflammation. Mutations in the ASAH1 gene are linked to a range of neurological disorders, most notably Farber disease, a rare lysosomal storage disorder characterized by the accumulation of ceramide in lysosomes. Research on ASAH1 has gained momentum due to its potential implications in both basic biology and therapeutic development. Understanding the structure, function, and regulatory mechanisms of ASAH1 can provide insights into the pathophysiology of related diseases and lead to the identification of novel intervention strategies. Additionally, the therapeutic manipulation of ASAH1 activity may offer promising approaches for treating conditions associated with ceramide accumulation, as well as broader implications for diseases involving sphingolipid metabolism. Consequently, the study of ASAH1 and its recombinant forms has significant potential for uncovering molecular targets for drug development and improving our understanding of lipid-related diseases.
